These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 18394022

  • 1. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
    Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Olijhoek JK, Visseren FL.
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):870-7. PubMed ID: 18394022
    [Abstract] [Full Text] [Related]

  • 2. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
    Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL.
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
    [Abstract] [Full Text] [Related]

  • 3. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
    Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL.
    Atherosclerosis; 2009 Jan; 202(1):216-24. PubMed ID: 18533158
    [Abstract] [Full Text] [Related]

  • 4. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.
    J Clin Lipidol; 2013 Jan; 7(4):292-303. PubMed ID: 23890516
    [Abstract] [Full Text] [Related]

  • 5. Fasting cholesteryl ester transfer protein concentration is independently associated with the postprandial decrease in high-density lipoprotein cholesterol concentration after fat-rich meals: the Hoorn prandial study.
    Alssema M, El-Harchaoui K, Schindhelm RK, Diamant M, Nijpels G, Kostense PJ, Teerlink T, Heine RJ, Dallinga-Thie GM, Kuivenhoven JA, Dekker JM, Scheffer PG.
    Metabolism; 2010 Jun; 59(6):854-60. PubMed ID: 20005542
    [Abstract] [Full Text] [Related]

  • 6. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study.
    Westerink J, Deanfield JE, Imholz BP, Spiering W, Basart DC, Coll B, Kastelein JJ, Visseren FL.
    Atherosclerosis; 2013 Mar; 227(1):118-24. PubMed ID: 23261174
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

  • 8. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
    Zubaid M, Shakir DK, Bazargani N, Binbrek A, Gopal R, Al-Tamimi O, Bakir S.
    J Cardiovasc Med (Hagerstown); 2008 Jul; 9(7):688-93. PubMed ID: 18545068
    [Abstract] [Full Text] [Related]

  • 9. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P.
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [Abstract] [Full Text] [Related]

  • 10. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
    Gupta M, Szmitko PE, Tsigoulis M, Braga MF, Kajil M, Herjikaka S, Quan A, Teoh H, Verma S.
    J Cardiovasc Pharmacol; 2010 Sep; 56(3):241-5. PubMed ID: 20505518
    [Abstract] [Full Text] [Related]

  • 11. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 12. Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus.
    de Vries R, Dikkeschei BD, Sluiter WJ, Dallinga-Thie GM, van Tol A, Dullaart RP.
    Clin Lab; 2012 Nov; 58(11-12):1231-9. PubMed ID: 23289194
    [Abstract] [Full Text] [Related]

  • 13. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
    Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, Pauciullo P, Marotta G, Fellin R, Gasparrini S, Piliego T.
    Nutr Metab Cardiovasc Dis; 1999 Oct; 9(5):234-43. PubMed ID: 10656170
    [Abstract] [Full Text] [Related]

  • 14. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

  • 15. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS, Bissonnette S, Habib R, Boukas S, Ezetrol Add-On Investigators.
    Ann Pharmacother; 2007 Sep 22; 41(9):1345-51. PubMed ID: 17666579
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
    Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J.
    Curr Med Res Opin; 2004 Jul 22; 20(7):1087-94. PubMed ID: 15265253
    [Abstract] [Full Text] [Related]

  • 17. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
    Sheu WH, Jeng CY, Lee WJ, Lin SY, Pei D, Chen YT.
    Metabolism; 2001 Mar 22; 50(3):355-9. PubMed ID: 11230791
    [Abstract] [Full Text] [Related]

  • 18. A deficiency of cholesteryl ester transfer protein whose serum remnant-like particle-triglyceride significantly increased, but serum remnant-like particle-cholesterol did not after an oral fat load.
    Ai M, Tanaka A, Shimokado K, Ohtani R, Inazu A, Kobayashi J, Mabuchi H, Nakano T, Nakajima K.
    Ann Clin Biochem; 2009 Nov 22; 46(Pt 6):457-63. PubMed ID: 19641010
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cholesteryl ester transfer protein in metabolic syndrome.
    Sandhofer A, Kaser S, Ritsch A, Laimer M, Engl J, Paulweber B, Patsch JR, Ebenbichler CF.
    Obesity (Silver Spring); 2006 May 22; 14(5):812-8. PubMed ID: 16855190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.